15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $4M | -$3M | -3.2% | -78.2% | -14.0% | -10.3% | $88937 | — | $345112 |
| 2024 | $5M | -$5M | -43.8% | -101.3% | -61.1% | -31.8% | -$444474 | — | $626879 |
| 2023 | $7M | -$3M | -4.0% | -39.2% | -41.3% | -18.7% | -$711203 | — | $1M |
| 2022 | $8M | -$4M | -6.1% | -43.8% | -92.6% | -22.3% | -$811509 | — | $2M |
| 2021 | $10M | -$3M | 3.6% | -29.7% | -56.5% | -15.0% | -$687893 | — | $5M |
| 2020 | $11M | -$3M | 18.0% | -23.7% | -35.8% | -13.6% | -$909567 | $5M | $957653 |
| 2019 | $11M | -$21M | 13.6% | -186.8% | -224.1% | -93.1% | $472309 | $4M | $1M |
| 2018 | $12M | -$11M | 16.0% | -84.7% | -35.6% | -23.7% | $2M | $7M | $1M |
| 2017 | $13M | -$19M | 18.7% | -141.4% | -44.8% | -32.2% | $704737 | $9M | $2M |
| 2016 | $16M | -$9M | 20.7% | -52.4% | -15.6% | -11.7% | $3M | — | $3M |
| 2015 | $20M | -$15M | 7.2% | -70.3% | -21.2% | -16.0% | $4M | — | $6M |
| 2014 | $22M | -$40M | 12.1% | -175.1% | -42.6% | -32.7% | $1M | — | — |
| 2013 | $33M | -$20M | -1.5% | -56.7% | -15.0% | -12.7% | $27M | — | — |
| 2012 | $55M | $5M | 25.8% | 10.8% | 3.1% | 2.8% | $4M | — | $4M |
| 2011 | $81M | $19M | 35.7% | 27.1% | 13.5% | 12.3% | $6M | — | $4M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $948340 | -$1M | 8.8% | -151.0% | -4.0% | -3.3% | — | — | $304874 |
| Mar '26 | $983536 | -$1M | 29.0% | -113.6% | -3.1% | -2.5% | — | — | $168474 |
| Dec '25 | $1M | -$1M | 12.3% | -97.9% | -5.4% | -3.9% | $151536 | — | $345112 |
| Sep '25 | $756217 | -$651482 | -7.9% | -83.1% | -7.8% | -4.1% | -$237598 | — | $267625 |
| Jun '25 | $1M | -$528367 | -8.5% | -63.6% | -8.2% | -3.8% | $274372 | — | $600000 |
| Mar '25 | $1M | -$785572 | -12.0% | -66.8% | -11.3% | -5.5% | -$132000 | — | $400000 |
| Dec '24 | $1M | -$1M | -14.2% | -105.5% | -15.8% | -8.2% | $279228 | — | $626879 |
| Sep '24 | $1M | -$1M | -47.2% | -98.6% | -17.1% | -8.3% | -$37732 | — | $700000 |
| Jun '24 | $924943 | -$1M | -109.8% | -150.4% | -19.4% | -10.1% | — | — | — |
| Mar '24 | $1M | -$955892 | -21.2% | -66.9% | -11.5% | — | — | — | — |
| Dec '23 | $2M | -$1M | -3.7% | -55.1% | -16.5% | -7.5% | — | — | $1M |
| Sep '23 | $2M | -$777600 | -12.9% | -39.6% | -12.7% | -5.1% | — | — | $1M |
| Jun '23 | $1M | -$593029 | -13.4% | -41.6% | -13.6% | -3.8% | — | — | $901910 |
| Mar '23 | $2M | -$475976 | 9.1% | -20.3% | -10.2% | -2.7% | — | — | $1M |
| Dec '22 | $3M | -$1M | 1.5% | -40.0% | -29.5% | -7.1% | $611862 | — | $2M |
| Sep '22 | $2M | -$790773 | -7.0% | -35.0% | -27.9% | -4.9% | -$33427 | — | $2M |
| Jun '22 | $2M | -$888394 | -14.2% | -48.3% | -22.1% | -5.0% | -$509114 | — | $2M |
| Mar '22 | $2M | -$1M | -10.6% | -56.8% | -19.3% | -4.9% | -$880830 | — | $4M |
| Dec '21 | $3M | -$980719 | 10.4% | -22.5% | -16.3% | -4.3% | -$205168 | — | $5M |
| Sep '21 | $2M | -$826669 | -15.0% | -38.5% | -12.1% | -4.5% | -$866823 | $4M | $458831 |
How the market has priced CPHI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, CHINA PHARMA HOLDINGS, INC.'s revenue has declined 17.5% per year. These are computed facts, not advice.
As of FY2025, CHINA PHARMA HOLDINGS, INC. reported — of total debt against $345112 of cash; operating income covered interest expense -118.8×.
In FY2025, gross margin was -3.2%, operating margin -78.2%, and net margin -76.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.